DISCOntinuation of disease-modifying therapies in Multiple Sclerosis (DISCOMS): Primary results of the extension trial

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2023
This article has no abstract
Epistemonikos ID: 3d622db35b1d0d78bc0edb3d705e42ed6133fe62
First added on: Apr 30, 2026